Summit Therapeutics Inc. (SMMT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Summit Therapeutics Inc. (SMMT) trades at $13.50 with AI Score 45/100 (Grade C). Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for infectious diseases. Market cap: $10.5B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 7, 2026SMMT stock analysis for 2026: Analysts have set a consensus price target of $29.33 for Summit Therapeutics Inc., suggesting 117.3% upside from the current price of $13.50. The AI MoonshotScore is 45/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SMMT: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Summit Therapeutics Inc. (SMMT) Healthcare & Pipeline Overview
Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel medicines targeting infectious diseases, particularly Clostridioides difficile infection (CDI). Their lead candidate, ridinilazole, is currently in Phase III clinical trials, positioning them to address a significant unmet need in the healthcare sector.
What Is the Investment Thesis for SMMT?
Summit Therapeutics Inc. presents a compelling investment thesis centered on the potential of ridinilazole to become a leading treatment for Clostridioides difficile infection (CDI). With Phase III clinical trials underway, positive results could drive significant value creation. The company's focus on addressing antibiotic resistance, particularly through SMT-738, aligns with growing global health concerns. However, the success of Summit Therapeutics hinges on the successful completion of clinical trials, regulatory approvals, and effective commercialization strategies. The current market capitalization of $10.5B reflects investor optimism, but the negative beta of -1.37 indicates sensitivity to market volatility. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's long-term potential.
Based on FMP financials and quantitative analysis
SMMT Key Highlights
- Lead product candidate ridinilazole is in Phase III clinical trials for Clostridioides difficile infection (CDI).
- Focus on combating multidrug-resistant infections with SMT-738, addressing a critical global health need.
- Market capitalization of $10.5B reflects investor confidence in the company's pipeline.
- Negative beta of -1.37 indicates lower correlation with overall market movements.
- Founded in 2003, Summit Therapeutics has a history of developing innovative therapies for infectious diseases.
Who Are SMMT's Competitors?
SMMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | $180.39 | -3.10% | $38.4B | 52 |
| RPRX Royalty Pharma plc | $58.36 | +0.31% | $25.1B | 81 |
| EXAS Exact Sciences Corporation | $104.91 | +0.00% | $20.0B | 62 |
| ROIV Roivant Sciences Ltd. | $34.05 | -1.33% | $24.5B | 39 |
| MRNA Moderna, Inc. | $61.82 | -2.11% | $25.0B | — |
| KRYS Krystal Biotech, Inc. | $339.22 | -4.41% | $10.0B | 100 |
| CORT Corcept Therapeutics Incorporated | $91.57 | +1.16% | $9.83B | 90 |
| TECH Bio-Techne Corporation | $71.64 | -0.67% | $11.2B | 89 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMMT's Key Strengths?
- Lead product candidate in Phase III clinical trials.
- Focus on addressing antibiotic resistance.
- Experienced management team.
- Strong intellectual property portfolio.
What Are SMMT's Weaknesses?
- Reliance on a single lead product candidate.
- High R&D expenses.
- Limited commercialization experience.
- Negative beta indicates higher volatility.
What Could Drive SMMT Stock Higher?
- Data readout from Phase III clinical trials for ridinilazole.
- Regulatory submissions for marketing approval of ridinilazole.
- Progress in the development of SMT-738 for multidrug-resistant infections.
- Expansion of strategic partnerships and collaborations.
What Are the Key Risks for SMMT?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for ridinilazole.
- Clinical trial failures or delays.
- Competition from other pharmaceutical companies.
- High R&D expenses and cash burn.
- Dependence on key personnel.
What Are the Growth Opportunities for SMMT?
- Successful Completion of Phase III Trials for Ridinilazole: The successful completion of Phase III clinical trials for ridinilazole represents a significant growth opportunity for Summit Therapeutics. Positive trial results would pave the way for regulatory approval and commercialization, potentially capturing a significant share of the CDI treatment market. Timeline: Anticipated data readout and regulatory submissions within the next 12-24 months.
- Expansion into New Geographic Markets: Expanding commercial operations into new geographic markets, particularly in Europe and Asia, presents another growth opportunity. CDI is a global health concern, and introducing ridinilazole in these regions could drive significant revenue growth. This expansion would require strategic partnerships, regulatory approvals, and investment in sales and marketing infrastructure. Timeline: Potential expansion within the next 3-5 years, contingent on regulatory approvals and market access.
- Development of SMT-738 for Multidrug-Resistant Infections: The development of SMT-738 for combating multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae, addresses a critical unmet need in the healthcare sector. Successful development and commercialization of SMT-738 could position Summit Therapeutics as a leader in the fight against antibiotic resistance. The market for treatments targeting multidrug-resistant infections is expected to grow significantly due to the increasing prevalence of these infections. Timeline: Ongoing preclinical and clinical development, with potential market entry in 5-7 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies and research institutions can accelerate the development and commercialization of Summit Therapeutics' pipeline. These partnerships can provide access to additional funding, expertise, and market access. Collaborations can also help to expand the company's pipeline and diversify its product portfolio. Timeline: Ongoing efforts to establish strategic partnerships and collaborations.
- Acquisition of Complementary Technologies and Assets: Acquiring complementary technologies and assets, such as novel drug delivery systems or diagnostic tools, can enhance Summit Therapeutics' competitive position and expand its capabilities. These acquisitions can provide access to new markets, technologies, and expertise. Strategic acquisitions can also help to diversify the company's pipeline and reduce its reliance on a single product candidate. Timeline: Ongoing evaluation of potential acquisition targets.
What Opportunities Does SMMT Have?
- Successful completion of clinical trials.
- Expansion into new geographic markets.
- Strategic partnerships and collaborations.
- Acquisition of complementary technologies.
What Threats Does SMMT Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Changes in healthcare policies and reimbursement.
What Are SMMT's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Specialized expertise in infectious disease treatment.
- Established relationships with key opinion leaders and healthcare providers.
What Does SMMT Do?
Founded in 2003 and headquartered in Cambridge, Massachusetts, Summit Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines aimed at treating infectious diseases. The company's primary focus is on Clostridioides difficile infection (CDI), a severe infection of the colon. Their lead product candidate, ridinilazole, is an orally administered small molecule antibiotic currently undergoing Phase III clinical trials for the treatment of CDI. Ridinilazole represents a potential advancement in CDI treatment due to its novel mechanism of action and promising clinical trial results. Beyond ridinilazole, Summit Therapeutics is also developing SMT-738, which targets multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae infections. Additionally, the company is advancing the DDS-04 series for potential treatment of infections caused by Enterobacteriaceae. Summit Therapeutics operates primarily in the United States and Latin America, conducting clinical programs and seeking regulatory approvals to bring its innovative therapies to market. The company's strategy involves rigorous clinical development, strategic partnerships, and a commitment to addressing critical unmet needs in infectious disease treatment.
What Products and Services Does SMMT Offer?
- Discovers and develops medicines for infectious diseases.
- Focuses on Clostridioides difficile infection (CDI) treatment.
- Conducts Phase III clinical trials for ridinilazole.
- Develops SMT-738 for multidrug-resistant infections.
- Offers DDS-04 series for Enterobacteriaceae infections.
- Commercializes medicines in the United States and Latin America.
How Does SMMT Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved products through sales and marketing efforts.
What Industry Does SMMT Operate In?
Summit Therapeutics operates within the biotechnology industry, which is characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The market for infectious disease treatments is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for novel therapies. Competitors such as Revolution Medicines, Inc. (RVMD), Royalty Pharma plc (RPRX), and Moderna, Inc. (MRNA) are also active in the biotechnology space, focusing on different therapeutic areas and approaches. Summit Therapeutics' focus on CDI and multidrug-resistant infections positions it to capitalize on the growing demand for targeted therapies in this sector.
Who Are SMMT's Key Customers?
- Hospitals and healthcare providers treating patients with CDI.
- Patients suffering from Clostridioides difficile infection.
- Pharmacies dispensing prescribed medications.
- Healthcare systems and managed care organizations.
Key Financial Metrics
Its free cash flow yield is -2.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.7%, the inverse of the P/E and a quick read on earnings relative to price.
How Summit Therapeutics Inc. Is Valued
Summit Therapeutics Inc. carries a market capitalization of $10.5B, placing it in the large-cap category. Relative to its peer group, SMMT's quantitative score of 45/100 is below the peer average of 59/100.
F-Score 1/9Financial Health
Summit Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 50.39 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Summit Therapeutics Inc. revenue of about $3.2M for fiscal 2026, with EPS near $-1.09. The estimate reflects 10 contributing analysts.
SMMT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's upcoming drug trials, indicating potential positive outcomes.
- Community sentiment has shifted positively as discussions around the company's novel therapies gain traction.
- Analysts are highlighting the potential of Summit's pipeline, particularly in rare diseases, attracting investor interest.
- Increased media coverage surrounding their advancements has sparked curiosity and optimism among retail investors.
Bear Case
- Concerns about the timeline for regulatory approvals have led to skepticism among some investors.
- Recent social sentiment shows a notable amount of caution, with bearish discussions about potential delays in clinical trials.
- Insider selling in the past month raises red flags about management's confidence in short-term prospects.
- Market perception remains cautious due to the overall volatility in the biotech sector, impacting investor sentiment negatively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SMMT Latest News
-
10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga · Jul 1, 2026
-
Daily – Vickers Top Buyers & Sellers for 06/15/2026
Argus Research · Jun 15, 2026
-
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Barchart · Jun 10, 2026
-
Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market Today
benzinga · Jun 10, 2026
SMMT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMMT.
Price Targets
Consensus target: $29.33
SMMT MoonshotScore
What does this score mean?
The MoonshotScore rates SMMT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
10 Health Care Stocks With Whale Alerts In Today’s Session
Daily – Vickers Top Buyers & Sellers for 06/15/2026
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market Today
Leadership: Robert W. Duggan
CEO
Robert W. Duggan is an accomplished executive with extensive experience in the healthcare and technology sectors. He has a proven track record of building and leading successful companies. Prior to joining Summit Therapeutics, Duggan held leadership positions at various biotechnology and pharmaceutical firms. His expertise spans strategic planning, product development, and commercialization. Duggan's leadership is characterized by a focus on innovation, patient-centricity, and value creation. He holds advanced degrees in business and science.
Track Record: Under Robert Duggan's leadership, Summit Therapeutics has advanced its lead product candidate, ridinilazole, into Phase III clinical trials. He has overseen the expansion of the company's pipeline and the strengthening of its intellectual property portfolio. Duggan has also been instrumental in securing strategic partnerships and collaborations to support the company's growth initiatives. His focus on innovation and execution has positioned Summit Therapeutics as a promising player in the infectious disease treatment market.
Summit Therapeutics Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SMMT?
SMMT holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for infectious diseases. Their lead product candidate, ridinilazole, is …
What does Summit Therapeutics Inc. do?
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases. Their primary focus is on Clostridioides difficile infection (CDI), a severe infection of the colon. The company's lead product candidate, ridinilazole, is an orally administered small molecule antibiotic currently in Phase III clinical trials for the treatment of CDI.
What do analysts say about SMMT stock?
Analyst coverage of Summit Therapeutics Inc. (SMMT) is focused on the potential of ridinilazole to address the Clostridioides difficile infection (CDI) market. Key valuation metrics include potential peak sales of ridinilazole and the probability of regulatory approval. Growth considerations center on the successful completion of Phase III trials and subsequent commercialization.
What are the main risks for SMMT?
The main risks for Summit Therapeutics Inc. include the potential failure of ridinilazole to achieve positive results in Phase III clinical trials, which could significantly impact the company's valuation. Regulatory hurdles and potential delays in obtaining marketing approval from agencies like the FDA also pose risks.
What are the key factors to evaluate for SMMT?
Summit Therapeutics Inc. (SMMT) holds an AI score of 45/100 (low). Analysts target $29.33 (+117%). Not financial advice.
How frequently does SMMT data refresh on this page?
SMMT's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SMMT's recent stock price performance?
Summit Therapeutics Inc. (SMMT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate in Phase III clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SMMT overvalued or undervalued right now?
Summit Therapeutics Inc. (SMMT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $29.33 (+117%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SMMT before investing?
Before investing in Summit Therapeutics Inc. (SMMT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual research and risk assessment.